Gastrointestinal dysmotility or obstruction

1 paper1 finding

Humans1

Associations

1

Semaglutide

upin humans1HR 3.91

1 study

Semaglutide raises the risk of gastrointestinal dysmotility or obstruction in humans (HR 3.91, 95% CI 1.42-10.82).
“gastrointestinal dysmotility or obstruction (3.91, 1.42-10.82)”
Humansfor weight loss vs matched non-initiatorsn = 2,357
GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study
Diabetes, obesity & metabolism6 Jul 2026

More on Semaglutide

Latest

1 in 12 months

Diabetes, Obesity & Metabolism7 Jul

GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study

Cohort study of 68,001 peopleGLP-1 receptor agonists